Prognostic gene expression signature for high-grade serous ovarian cancer

Background - Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic si...

Full description

Saved in:
Bibliographic Details
Main Authors: Millstein, Joshua (Author) , Turzanski Fortner, Renée (Author) , Sinn, Peter (Author)
Other Authors: Chang-Claude, Jenny (Other) , Herpel, Esther (Other)
Format: Article (Journal)
Language:English
Published: 28 May 2020
In: Annals of oncology
Year: 2020, Volume: 31, Issue: 9, Pages: 1240-1250
ISSN:1569-8041
DOI:10.1016/j.annonc.2020.05.019
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2020.05.019
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0923753420398410
Get full text
Author Notes:J. Millstein, T. Budden, E.L. Goode, M.S. Anglesio, A. Talhouk, M.P. Intermaggio, H.S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R.C. Bentley, C. Wang, D.S. Chiu, S. Kommoss, S.C.Y. Leung, J. Senz, A. Lum, V. Chow, H. Sudderuddin, R. Mackenzie, J. George, AOCS Group, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Köbel, I.A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramón y Cajal, J. García-Donas, S. Hernando Polo, G.C. Rodriguez, K.L. Cushing-Haugen, H.R. Harris, C.S. Greene, R.A. Zelaya, S. Behrens, R.T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubiński, O. Oszurek, A. Tołoczko, C. Cybulski, J. Menkiszak, C.L. Pearce, M.C. Pike, C. Tseng, J. Alsop, V. Rhenius, H. Song, M. Jimenez-Linan, A.M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C.J. Kennedy, R. Sharma, P.R. Harnett, B. Gao, S.E. Johnatty, R. Sayer, J. Boros, S.J. Winham, G.L. Keeney, S.H. Kaufmann, M.C. Larson, H. Luk, B.Y. Hernandez, P.J. Thompson, L.R. Wilkens, M.E. Carney, B. Trabert, J. Lissowska, L. Brinton, M.E. Sherman, C. Bodelon, S. Hinsley, L.A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I. Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A.H. Wu, U. Menon, M.T. Goodman, J.M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. deFazio, S.A. Gayther, M.J. García, M.J. Henderson, M.A. Rossing, A. Beeghly-Fadiel, P A. Fasching, S. Orsulic, B.Y. Karlan, G.E. Konecny, D.G. Huntsman, D.D. Bowtell, J.D. Brenton, J.A. Doherty, P.D.P. Pharoah & S.J. Ramus

MARC

LEADER 00000caa a2200000 c 4500
001 1733951806
003 DE-627
005 20220818212451.0
007 cr uuu---uuuuu
008 200929s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.annonc.2020.05.019  |2 doi 
035 |a (DE-627)1733951806 
035 |a (DE-599)KXP1733951806 
035 |a (OCoLC)1341367936 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Millstein, Joshua  |e VerfasserIn  |0 (DE-588)1218566736  |0 (DE-627)1733956263  |4 aut 
245 1 0 |a Prognostic gene expression signature for high-grade serous ovarian cancer  |c J. Millstein, T. Budden, E.L. Goode, M.S. Anglesio, A. Talhouk, M.P. Intermaggio, H.S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R.C. Bentley, C. Wang, D.S. Chiu, S. Kommoss, S.C.Y. Leung, J. Senz, A. Lum, V. Chow, H. Sudderuddin, R. Mackenzie, J. George, AOCS Group, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Köbel, I.A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramón y Cajal, J. García-Donas, S. Hernando Polo, G.C. Rodriguez, K.L. Cushing-Haugen, H.R. Harris, C.S. Greene, R.A. Zelaya, S. Behrens, R.T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubiński, O. Oszurek, A. Tołoczko, C. Cybulski, J. Menkiszak, C.L. Pearce, M.C. Pike, C. Tseng, J. Alsop, V. Rhenius, H. Song, M. Jimenez-Linan, A.M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C.J. Kennedy, R. Sharma, P.R. Harnett, B. Gao, S.E. Johnatty, R. Sayer, J. Boros, S.J. Winham, G.L. Keeney, S.H. Kaufmann, M.C. Larson, H. Luk, B.Y. Hernandez, P.J. Thompson, L.R. Wilkens, M.E. Carney, B. Trabert, J. Lissowska, L. Brinton, M.E. Sherman, C. Bodelon, S. Hinsley, L.A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I. Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A.H. Wu, U. Menon, M.T. Goodman, J.M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. deFazio, S.A. Gayther, M.J. García, M.J. Henderson, M.A. Rossing, A. Beeghly-Fadiel, P A. Fasching, S. Orsulic, B.Y. Karlan, G.E. Konecny, D.G. Huntsman, D.D. Bowtell, J.D. Brenton, J.A. Doherty, P.D.P. Pharoah & S.J. Ramus 
264 1 |c 28 May 2020 
300 |b Diagramme 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a AOCS Study Group: D. Bowtell, G. Chenevix-Trench, A. Green, P. Webb, A. DeFazio, D. Gertig, N. Traficante, S. Fereday, S. Moore, J. Hung, K. Harrap, T. Sadkowsky, N. Pandeya, M. Malt, A. Mellon, R. Robertson, T. Vanden Bergh, M. Jones, P. Mackenzie, J. Maidens, K. Nattress, Y.E. Chiew, A. Stenlake, H. Sullivan, B. Alexander, P. Ashover, S. Brown, T. Corrish, L. Green, L. Jackman, K. Ferguson, K. Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, P. Mamers, L. Bowes, L. Galletta, D. Giles, J. Hendley, K. Alsop, T. Schmidt, H. Shirley, C. Ball, C. Young, S. Viduka, Hoa Tran, Sanela Bilic, Lydia Glavinas, Julia Brooks, R. Stuart-Harris, F. Kirsten, J. Rutovitz, P. Clingan, A. Glasgow, A. Proietto, S. Braye, G. Otton, J. Shannon, T. Bonaventura, J. Stewart, S. Begbie, M. Friedlander, D. Bell, S. Baron-Hay, A. Ferrier, G. Gard, D. Nevell, N. Pavlakis, S. Valmadre, B. Young, C. Camaris, R. Crouch, L. Edwards, N. Hacker, D. Marsden, G. Robertson, P. Beale, J. Beith, J. Carter, C. Dalrymple, R. Houghton, P. Russell, M. Links, J. Grygiel, J. Hill, A. Brand, K. Byth, R. Jaworski, P. Harnett, R. Sharma, G. Wain, B. Ward, D. Papadimos, A. Crandon, M. Cummings, K. Horwood, A. Obermair, L. Perrin, D. Wyld, J. Nicklin, M. Davy, M.K. Oehler, C. Hall, T. Dodd, T. Healy, K. Pittman, D. Henderson, J. Miller, J. Pierdes, P. Blomfield, D. Challis, R. McIntosh, A. Parker, B. Brown, R. Rome, D. Allen, P. Grant, S. Hyde, R. Laurie, M. Robbie, D. Healy, T. Jobling, T. Manolitsas, J. McNealage, P. Rogers, B. Susil, E. Sumithran, I. Simpson, K. Phillips, D. Rischin, S. Fox, D. Johnson, S. Lade, M. Loughrey, N. O’Callaghan, W. Murray, P. Waring, V. Billson, J. Pyman, D. Neesham, M. Quinn, C. Underhill, R. Bell, L.F. Ng, R. Blum, V. Ganju, I. Hammond, Y. Leung, A. McCartney, M. Buck, I. Haviv, D. Purdie, D. Whiteman, N. Zeps 
500 |a Gesehen am 29.09.2020 
520 |a Background - Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. - Patients and methods - Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. - Results - Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. - Conclusion - The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches. 
650 4 |a formalin-fixed paraffin-embedded 
650 4 |a gene expression 
650 4 |a high-grade serous ovarian cancer 
650 4 |a overall survival 
650 4 |a prognosis 
700 1 |a Turzanski Fortner, Renée  |e VerfasserIn  |0 (DE-588)1198723726  |0 (DE-627)1680898272  |4 aut 
700 1 |a Chang-Claude, Jenny  |0 (DE-588)1049304993  |0 (DE-627)781626188  |0 (DE-576)168344475  |4 oth 
700 1 |a Sinn, Peter  |d 1957-  |e VerfasserIn  |0 (DE-588)1022590944  |0 (DE-627)717004783  |0 (DE-576)365646342  |4 aut 
700 1 |a Herpel, Esther  |d 1973-  |0 (DE-588)12965227X  |0 (DE-627)476593662  |0 (DE-576)297767984  |4 oth 
773 0 8 |i Enthalten in  |t Annals of oncology  |d Amsterdam [u.a.] : Elsevier, 1990  |g 31(2020), 9, Seite 1240-1250  |h Online-Ressource  |w (DE-627)320428796  |w (DE-600)2003498-2  |w (DE-576)098134345  |x 1569-8041  |7 nnas  |a Prognostic gene expression signature for high-grade serous ovarian cancer 
773 1 8 |g volume:31  |g year:2020  |g number:9  |g pages:1240-1250  |g extent:11  |a Prognostic gene expression signature for high-grade serous ovarian cancer 
856 4 0 |u https://doi.org/10.1016/j.annonc.2020.05.019  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0923753420398410  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200929 
993 |a Article 
994 |a 2020 
998 |g 12965227X  |a Herpel, Esther  |m 12965227X:Herpel, Esther  |d 910000  |d 912000  |d 50000  |e 910000PH12965227X  |e 912000PH12965227X  |e 50000PH12965227X  |k 0/910000/  |k 1/910000/912000/  |k 0/50000/  |p 202 
998 |g 1022590944  |a Sinn, Peter  |m 1022590944:Sinn, Peter  |d 910000  |d 912000  |d 50000  |e 910000PS1022590944  |e 912000PS1022590944  |e 50000PS1022590944  |k 0/910000/  |k 1/910000/912000/  |k 0/50000/  |p 201 
998 |g 1049304993  |a Chang-Claude, Jenny  |m 1049304993:Chang-Claude, Jenny  |d 50000  |e 50000PC1049304993  |k 0/50000/  |p 255 
998 |g 1198723726  |a Turzanski Fortner, Renée  |m 1198723726:Turzanski Fortner, Renée  |d 50000  |e 50000PT1198723726  |k 0/50000/  |p 200 
999 |a KXP-PPN1733951806  |e 3763897259 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"family":"Millstein","display":"Millstein, Joshua","given":"Joshua","role":"aut"},{"role":"aut","given":"Renée","family":"Turzanski Fortner","display":"Turzanski Fortner, Renée"},{"role":"oth","given":"Jenny","display":"Chang-Claude, Jenny","family":"Chang-Claude"},{"display":"Sinn, Peter","family":"Sinn","role":"aut","given":"Peter"},{"family":"Herpel","display":"Herpel, Esther","role":"oth","given":"Esther"}],"id":{"doi":["10.1016/j.annonc.2020.05.019"],"eki":["1733951806"]},"relHost":[{"id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"recId":"320428796","physDesc":[{"extent":"Online-Ressource"}],"disp":"Prognostic gene expression signature for high-grade serous ovarian cancerAnnals of oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}],"origin":[{"dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"pubHistory":["1.1990 -"],"part":{"extent":"11","volume":"31","pages":"1240-1250","year":"2020","text":"31(2020), 9, Seite 1240-1250","issue":"9"},"language":["eng"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}]}],"recId":"1733951806","physDesc":[{"extent":"11 S.","noteIll":"Diagramme"}],"name":{"displayForm":["J. Millstein, T. Budden, E.L. Goode, M.S. Anglesio, A. Talhouk, M.P. Intermaggio, H.S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R.C. Bentley, C. Wang, D.S. Chiu, S. Kommoss, S.C.Y. Leung, J. Senz, A. Lum, V. Chow, H. Sudderuddin, R. Mackenzie, J. George, AOCS Group, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Köbel, I.A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramón y Cajal, J. García-Donas, S. Hernando Polo, G.C. Rodriguez, K.L. Cushing-Haugen, H.R. Harris, C.S. Greene, R.A. Zelaya, S. Behrens, R.T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubiński, O. Oszurek, A. Tołoczko, C. Cybulski, J. Menkiszak, C.L. Pearce, M.C. Pike, C. Tseng, J. Alsop, V. Rhenius, H. Song, M. Jimenez-Linan, A.M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C.J. Kennedy, R. Sharma, P.R. Harnett, B. Gao, S.E. Johnatty, R. Sayer, J. Boros, S.J. Winham, G.L. Keeney, S.H. Kaufmann, M.C. Larson, H. Luk, B.Y. Hernandez, P.J. Thompson, L.R. Wilkens, M.E. Carney, B. Trabert, J. Lissowska, L. Brinton, M.E. Sherman, C. Bodelon, S. Hinsley, L.A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I. Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A.H. Wu, U. Menon, M.T. Goodman, J.M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. deFazio, S.A. Gayther, M.J. García, M.J. Henderson, M.A. Rossing, A. Beeghly-Fadiel, P A. Fasching, S. Orsulic, B.Y. Karlan, G.E. Konecny, D.G. Huntsman, D.D. Bowtell, J.D. Brenton, J.A. Doherty, P.D.P. Pharoah & S.J. Ramus"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Prognostic gene expression signature for high-grade serous ovarian cancer","title_sort":"Prognostic gene expression signature for high-grade serous ovarian cancer"}],"note":["AOCS Study Group: D. Bowtell, G. Chenevix-Trench, A. Green, P. Webb, A. DeFazio, D. Gertig, N. Traficante, S. Fereday, S. Moore, J. Hung, K. Harrap, T. Sadkowsky, N. Pandeya, M. Malt, A. Mellon, R. Robertson, T. Vanden Bergh, M. Jones, P. Mackenzie, J. Maidens, K. Nattress, Y.E. Chiew, A. Stenlake, H. Sullivan, B. Alexander, P. Ashover, S. Brown, T. Corrish, L. Green, L. Jackman, K. Ferguson, K. Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, P. Mamers, L. Bowes, L. Galletta, D. Giles, J. Hendley, K. Alsop, T. Schmidt, H. Shirley, C. Ball, C. Young, S. Viduka, Hoa Tran, Sanela Bilic, Lydia Glavinas, Julia Brooks, R. Stuart-Harris, F. Kirsten, J. Rutovitz, P. Clingan, A. Glasgow, A. Proietto, S. Braye, G. Otton, J. Shannon, T. Bonaventura, J. Stewart, S. Begbie, M. Friedlander, D. Bell, S. Baron-Hay, A. Ferrier, G. Gard, D. Nevell, N. Pavlakis, S. Valmadre, B. Young, C. Camaris, R. Crouch, L. Edwards, N. Hacker, D. Marsden, G. Robertson, P. Beale, J. Beith, J. Carter, C. Dalrymple, R. Houghton, P. Russell, M. Links, J. Grygiel, J. Hill, A. Brand, K. Byth, R. Jaworski, P. Harnett, R. Sharma, G. Wain, B. Ward, D. Papadimos, A. Crandon, M. Cummings, K. Horwood, A. Obermair, L. Perrin, D. Wyld, J. Nicklin, M. Davy, M.K. Oehler, C. Hall, T. Dodd, T. Healy, K. Pittman, D. Henderson, J. Miller, J. Pierdes, P. Blomfield, D. Challis, R. McIntosh, A. Parker, B. Brown, R. Rome, D. Allen, P. Grant, S. Hyde, R. Laurie, M. Robbie, D. Healy, T. Jobling, T. Manolitsas, J. McNealage, P. Rogers, B. Susil, E. Sumithran, I. Simpson, K. Phillips, D. Rischin, S. Fox, D. Johnson, S. Lade, M. Loughrey, N. O’Callaghan, W. Murray, P. Waring, V. Billson, J. Pyman, D. Neesham, M. Quinn, C. Underhill, R. Bell, L.F. Ng, R. Blum, V. Ganju, I. Hammond, Y. Leung, A. McCartney, M. Buck, I. Haviv, D. Purdie, D. Whiteman, N. Zeps","Gesehen am 29.09.2020"],"origin":[{"dateIssuedDisp":"28 May 2020","dateIssuedKey":"2020"}]} 
SRT |a MILLSTEINJPROGNOSTIC2820